Literature DB >> 10233668

Stromelysin-3 (ST-3): immunohistochemical characterization of the matrix metalloproteinase (MMP)-11 in benign and malignant skin tumours and other skin disorders.

M Thewes1, W I Worret, R Engst, J Ring.   

Abstract

Matrix metalloproteinases (MMP) are involved in remodelling of the extracellular matrix (ECM) proteins suggesting that they play an important role in inflammatory process, in tumour invasion and metastasis. We examined immunohistochemically 330 cases of different skin disorders with the monoclonal antibody against MMP 11, stromelysin-3 (ST-3) protein. We found a positive immunoreactivity in fibroblasts surrounding malignant epithelial tumour cells in 63 of 125 cases (50.4%) of basal cell carcinomas, in four of 25 (16%) squamous cell carcinomas, whereas the tumour cells themselves were negative. Furthermore, the ST-3 protein could be detected in 23 of 40 cases (57.5%) of dermatofibroma, in two of five cases (40%) of atypical fibroxanthoma, in one of eight cases (12.5%) of dermatofibrosarcoma protuberans and, locally, in one of 10 cases (10%) of malignant fibrous histiocytoma. It was not present in the following skin lesions: keratoakanthomas (n = 12), Bowen's disease (n = 10), malignant melanoma (n = 12), melanocytic nevi (n = 28) and Kaposi's sarcomas (n = 25). In eczema (n = 10), psoriasis (n = 10) and virus-induced tissues (i.e. condylomata acuminata, n = 10) we did not observe an expression of ST-3 protein. We conclude first that ST-3 protein is a fibroblastic factor expressed in stromal cells adjacent to carcinoma cells; second, that ST-3 protein seems to be associated with benign fibroblastic tumours; and third, that it does not play a role in eczema, psoriasis or virus-induced skin lesions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233668     DOI: 10.1046/j.1365-2230.1999.00431.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  6 in total

1.  Gene profiling of the rat medial collateral ligament during early healing using microarray analysis.

Authors:  Connie S Chamberlain; Sabrina H Brounts; David G Sterken; Kevin I Rolnick; Geoffrey S Baer; Ray Vanderby
Journal:  J Appl Physiol (1985)       Date:  2011-05-19

2.  The Increased Expression of Matrix Metalloproteinase-9 Messenger RNA in the Non-lesional Skin of Patients with Large Plaque Psoriasis Vulgaris.

Authors:  Sang Eun Lee; Wook Lew
Journal:  Ann Dermatol       Date:  2009-02-28       Impact factor: 1.444

3.  Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer.

Authors:  Guelaguetza Vazquez-Ortiz; Patricia Pina-Sanchez; Karla Vazquez; Alfonso Duenas; Lucia Taja; Patricia Mendoza; José A Garcia; Mauricio Salcedo
Journal:  BMC Cancer       Date:  2005-06-30       Impact factor: 4.430

4.  Study of matrix metalloproteinases and their inhibitors in prostate cancer.

Authors:  S Escaff; J M Fernández; L O González; A Suárez; S González-Reyes; J M González; F J Vizoso
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

Review 5.  Matrix metalloproteinases in keratinocyte carcinomas.

Authors:  Pilvi Riihilä; Liisa Nissinen; Veli-Matti Kähäri
Journal:  Exp Dermatol       Date:  2020-09-17       Impact factor: 3.960

6.  The immunoexpression of MMP-1 and MMP-13 in eyelid basal cell carcinoma.

Authors:  Irina Maria Mercuţ; Cristiana Eugenia Simionescu; Alex Emilian Stepan; Bianca Cătălina Andreiana; Ana Maria Ciurea; Răzvan Mercuţ; Marius Eugen Ciurea
Journal:  Rom J Morphol Embryol       Date:  2020 Oct-Dec       Impact factor: 1.033

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.